Extraordinary General Meeting of BioGaia
The Extraordinary General Meeting of BioGaia AB (publ) on 18 March 2016 resolved on: · the approval of BioGaia’s transfers of 2,250 shares in BioGaia’s subsidiary Infant Bacterial Therapeutics AB (“IBT”) to each of Eamonn Connolly and Staffan Strömberg; and · the distribution of all BioGaia’s shares, namely 74,066 shares of series A and 1,659,579 shares of series B, in IBT, to BioGaia’s shareholders whereby one (1) series A share in BioGaia shall entitle to one (1) series A share fraction in IBT and one (1) series B share in BioGaia shall entitle to one (1) series B share fraction